<DOC>
	<DOCNO>NCT02244658</DOCNO>
	<brief_summary>Chemotherapy-related myelosuppression usually occur AML patient , induces severe thrombocytopenia haemorrhage , lead cause death . This clinical trial aim evaluate efficacy safety rhTPO management chemotherapy-induced thrombocytopenia acute myelocytic leukemia .</brief_summary>
	<brief_title>Recombinant Human Thrombopoietin ( rhTPO ) Management Chemotherapy-induced Thrombocytopenia Acute Myelocytic Leukemia</brief_title>
	<detailed_description>The investigator undertake parallel group , multicentre , randomize control trial 80 adult chemotherapy-induced thrombocytopenia 8 medical center China . AML patient PLT count &lt; 30×10^9/L previous cycle chemotherapy randomize two group one receive rhTPO 1.0μg/kg·d subcutaneously 7~14 consecutive day receive rhTPO thrombopoietic factor . Platelet count , bleed symptom evaluate treatment . Adverse event also record throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML patient PLT count &lt; 30×10^9/L previous cycle chemotherapy minimize risk clinically significant bleeding . allergic history biological agent ; history thrombotic hemorrhagic disease ; M3 M7 subtype ; pregnancy ; hypertension ; cardiovascular disease ; diabetes ; liver kidney function impairment ;</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>chemotherapy-induced thrombocytopenia</keyword>
	<keyword>recombinant human thrombopoietin</keyword>
	<keyword>acute myelocytic leukemia</keyword>
</DOC>